The estimated Net Worth of Dominic Piscitelli is at least $1.45 Million dollars as of 15 December 2023. Mr Piscitelli owns over 14,042 units of Oric Pharmaceuticals stock worth over $882,001 and over the last 8 years he sold ORIC stock worth over $0. In addition, he makes $568,839 as Chief Financial Officer at Oric Pharmaceuticals.
Sign up
Mr CPA ORIC stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Oric Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,042 units of ORIC stock worth $139,016 on 15 December 2023.
The largest trade he's ever made was buying 60,000 units of Oric Pharmaceuticals stock on 31 March 2022 worth over $321,600. On average, Mr trades about 9,006 units every 141 days since 2017. As of 15 December 2023 he still owns at least 89,091 units of Oric Pharmaceuticals stock.
You can see the complete history of Mr Piscitelli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Dominic G. Piscitelli CPA, M.B.A., CPA biography
Dominic G. Piscitelli CPA, M.B.A., CPA is the Chief Financial Officer at Oric Pharmaceuticals.
What is the salary of Mr CPA?
As the Chief Financial Officer of Oric Pharmaceuticals, the total compensation of Mr CPA at Oric Pharmaceuticals is $568,839. There are 3 executives at Oric Pharmaceuticals getting paid more, with Dr. Jacob M. Chacko M.B.A., M.D. having the highest compensation of $790,955.
How old is Mr CPA?
Mr CPA is 46, he's been the Chief Financial Officer of Oric Pharmaceuticals since . There are 8 older and 2 younger executives at Oric Pharmaceuticals. The oldest executive at Oric Pharmaceuticals, Inc. is Dr. Richard A. Heyman Ph.D., 64, who is the Co-Founder, Independent Chairman & Member of Scientific Advisory Board.
What's Mr CPA's mailing address?
Dominic's mailing address filed with the SEC is 10421 Pacific Center Ct, San Diego, CA 92121, USA.
Insiders trading at Oric Pharmaceuticals
Over the last 5 years, insiders at Oric Pharmaceuticals have traded over $33,873,532 worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth $12,330,600 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon und Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $996,237. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth $76,875.
What does Oric Pharmaceuticals do?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
What does Oric Pharmaceuticals's logo look like?
Complete history of Mr Piscitelli stock trades at AnaptysBio Inc und Oric Pharmaceuticals
Oric Pharmaceuticals executives and stock owners
Oric Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Jacob M. Chacko M.B.A., M.D.,
Pres, CEO & Director -
Dr. Pratik S. Multani M.D., M.S.,
Chief Medical Officer -
Dr. Pratik S. Multani,
Chief Medical Officer -
Dominic G. Piscitelli CPA, M.B.A., CPA,
Chief Financial Officer -
Dr. Richard A. Heyman Ph.D.,
Co-Founder, Independent Chairman & Member of Scientific Advisory Board -
Dr. Christian V. Kuhlen Esq., J.D., M.D.,
Gen. Counsel -
Matthew Panuwat,
Chief Bus. Officer -
Dr. Edna Chow Maneval,
Sr. VP of Clinical Devel. -
Dr. Christian V. Kuhlen J.D., M.D., Esq.,
Gen. Counsel -
Dr. Lori Sickels Friedman Ph.D.,
Chief Scientific Officer -
Dr. Scott W. Lowe Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Mardi Dier,
-
Richard A. Heyman,
-
Peter Svennilson,
Director -
Group Ii, Lp Column Group I...,
-
Dominic Piscitelli,
Chief Financial Officer -
Fund L.P.Topspin Biotech Fu...,
-
Richard H Scheller,
Director -
Advisors Llc Orbi Med Capit...,
-
Pratik S Multani,
Chief Medical Officer -
Carl L Gordon,
Director -
Steven L. Hoerter,
-
Angie You,
-
Group Ii, Lp Column Group I...,
-
Jacob Chacko,
PRESIDENT AND CEO -
Lori Anne Kunkel,